AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Aurora Cannabis Inc.
Video analysis: ACB
All videosNo video analysis for this stock yet. Request one from our team.
News: ACB
$250,000 in These 3 High-Income ETFs Could Pay You ~$2,800 a Month
Options-income ETFs now offer monthly payouts that dwarf what traditional dividend stocks provide, but before you move a dollar, there are tax mechanics and capital preservation risks that most income investors completely overlook.
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
EDMONTON, AB, Sept. 9, 2026 /PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a biopharmaceutical leader with 25 years of experience, will join the company as Executive Vice President, Global Commercial, effective September 28, 2026.
Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders
Curaleaf Responds to Aurora Circular; Reaffirms Offer as the Best Path to Value Creation for Shareholders PR Newswire
Aurora Cannabis Calls Curaleaf Offer Inadequate, Urges Rejection
Aurora Cannabis is urging its shareholders to reject an unsolicited $272 million hostile takeover bid from Curaleaf Holdings.
Aurora Cannabis Urges Shareholders to REJECT Curaleaf's Hostile Bid, Warning that it is Inadequate, Undervalues Aurora and Puts Shareholder Value and Future Upside at Risk
NASDAQ | TSX: ACB Curaleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discount Aurora is debt free and holds $149 million in cash 1 , Curaleaf carries over $1 billion in debt 2 , Aurora shareholders' own cash should not be used to help fix Curaleaf's balance sheet The hostile bid exposes Aurora shareholders to significant risks not fairly disclosed and could meaningfully weaken shareholder rights Aurora's transformation into a global, high-margin medical cannabis leader is delivering results, and the Board believes significant value creation lies ahead Aurora Files Directors' Circular Unanimously Recommending Shareholders REJECT Curaleaf's Hostile Bid by TAKING NO ACTION and NOT TENDERING their shares To keep current with and obtain information about the hostile bid, please visit www.ProtectAurora.com EDMONTON, AB, Sept. 2, 2026 /PRNewswire/ -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NASDAQ: ACB), the leading Canadian-based global medical cannabis company, today urged shareholders to reject the unsolicited take-over bid ("Hostile Bid") from Curaleaf Holdings, Inc. ("Curaleaf") (TSX: CURA) (OTCQX: CURLF), warning that the Hostile Bid would put Aurora shareholders' value and future upside at risk.
Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?
Curaleaf is offering Aurora shareholders $4 per share. Aurora believes Curaleaf's hostile bid undervalues the company.
Curaleaf Responds to Aurora Cannabis' Latest Attempt to Deflect From Shareholder Value Creation
Aurora's selective statistics and misleading characterization of engagement do not obscure years of underperformance and lost shareholder value Curaleaf reiterates its willingness to meet anytime to discuss a deal in the best interests of shareholders STAMFORD, Conn., Aug. 24, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today responded to Aurora Cannabis Inc.'s (TSX: ACB) (NASDAQ: ACB) ("Aurora") latest public statements regarding Curaleaf's offer for Aurora: "Aurora's hollow protests and completely misleading statistics change nothing about reality: if its multi-year turnaround strategy were delivering the value management claims, the company's valuation would reflect it.
AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID
Curaleaf's self-serving portrayal of our business is an attempt to acquire Aurora's world class EU-GMP manufacturing facilities and global medical cannabis footprint at the lowest price possible Aurora's international strategy is working; net revenue is up 17%YOY Contrary to Curaleaf's inaccurate statements, Aurora's high margin German business is growing and continues to be a key driver of Aurora's international growth strategy Shareholders are advised to TAKE NO ACTION pending formal recommendation from the Board and Special Committee. Offer remains open for at least 105 days from the launch of the Hostile Bid Questions about the Offer or would like to stay informed?
